
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Jubilant Pharmova will transfer its API business to subsidiary Jubilant Biosys via a slump sale. The division recorded Rs.609 crore revenue in FY25. Jubilant Pharmova share price dropped 1.74% to Rs.1,125 post-announcement on the BSE..
Jubilant Pharmova Ltd announced on June 12 that its board has approved the sale and transfer of its active pharmaceutical ingredient (API) business to Jubilant Biosys Ltd, a wholly-owned subsidiary. The transaction will be executed as a slump sale and is expected to be completed by September 1, 2025, subject to regulatory and procedural approvals.
The sale marks a structural reshuffle within the group, aimed at streamlining operations by transferring the API vertical into a subsidiary focused on global drug discovery services.
Also read: DCM Shriram to Acquire Hindusthan Specialty Chemicals for Rs. 375 Crore
API division revenue (FY25): Rs.609 crore (8.35% of consolidated revenue).
Net worth of API division: Rs.666.5 crore (10.68% of consolidated net worth).
Transfer mode: Slump sale, mainly through share issuance.
Completion timeline: On or before September 1, 2025.
Jubilant Pharmova share price: Closed at Rs.1,125, down 1.74%.
Also read: Genus Power: GIC Affiliate Plans Rs.650 Crore Stake Sale via Block Deal
The deal qualifies as a related party transaction, as Jubilant Biosys is a wholly-owned subsidiary of Jubilant Pharmova. However, the company confirmed the transaction would occur on an arm’s length basis. The sale is not part of any Scheme of Arrangement, and hence Regulation 37A of SEBI Listing Regulations is not applicable.
The consideration will be determined based on the book value of assets and liabilities of the API division as of the appointed date.
Business Unit | Details |
Division Transferred | API Business |
Revenue (FY25) | Rs.609 crore |
Net Worth (as of Mar 2025) | Rs.666.5 crore |
Share of Consolidated Rev. | 8.35% |
Share of Consolidated NW | 10.68% |
Transfer Completion Date | By September 1, 2025 |
This internal restructuring allows Jubilant Pharmova to consolidate research-focused businesses under Jubilant Biosys while maintaining group control. By realigning the API vertical into a specialised unit, the company aims to boost operational focus across product categories.
Following the announcement, Jubilant Pharmova share price declined by Rs.19.90, or 1.74%, on the BSE, closing at Rs.1,125. Despite the dip, the move is viewed as part of the company’s broader strategy to enhance organisational efficiency and business alignment.
Jubilant Pharmova share price may continue to reflect short-term volatility until the completion of the transaction, depending on regulatory progress and integration outcomes.
Also read: Oil Prices Soar 11% as Israeli Strikes on Iran Trigger Supply Fears
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading